Shukra Pharmaceuticals (524632) Q2 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 24/25 earnings summary
13 Jun, 2025Executive summary
Board approved unaudited financial results for Q2 and H1 FY2024-25 on 14 Nov 2024.
Audit Committee reviewed related party transactions for H1 FY2024-25.
Financial highlights
Q2 FY2024-25 revenue from operations: ₹2,463.83 lakh, up from ₹873.32 lakh in Q2 FY2023-24.
Net profit for Q2 FY2024-25: ₹48.53 lakh, compared to ₹102.42 lakh in Q2 FY2023-24.
H1 FY2024-25 net profit: ₹470.93 lakh, up from ₹512.95 lakh in H1 FY2023-24.
Basic and diluted EPS for Q2 FY2024-25: ₹0.11, down from ₹0.25 in Q2 FY2023-24.
Outlook and guidance
Statutory auditors issued an unqualified review report for Q2 FY2024-25.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Shukra Pharmaceuticals
- Sales and exports surged, but higher depreciation cut profit as injectable expansion advanced.524632
Q4 96/97 - Sales grew 18%, profit rose, and injectable production was poised to begin amid operating cash outflow.524632Q4 97/98
- Sales and exports surged as expansion funding coincided with negative operating cash flow.524632Q4 99/00
- Turnover rose 22.72%; injection-plant launch awaited regulatory approval.524632Q4 98/99
- Higher sales, lower PAT after a ₹5.65m write-off, and restructuring define FY16.524632Q4 15/16
- Revenue surged, but profit collapsed amid qualified audit and compliance concerns.524632Q4 19/20
- Revenue and profit surged; net debt turned negative and a ₹1 dividend was proposed.524632Q4 23/24
- FY23 earnings surged as export growth advanced alongside higher receivables and tax exposure.524632Q4 22/23
- A bank settlement lifted FY12 profit despite declining revenue and restructuring pressures.524632Q4 11/12
- Revenue declined, losses deepened, and restructuring remained central to the outlook.524632Q4 12/13